PET imaging agent flutemetamol showed 93.1% sensitivity and 93.3% specificity in identifying patients with clinically probable Alzheimer's disease, according to a Phase II study. Scans that ran a week later on the same patient group showed similar results. "These data show that flutemetamol exhibits equivalent brain uptake to that of its parent molecule, 11C-Pittsburgh compound B, while also providing high test-retest replicability and potentially greater accessibility for clinical and research use," a researcher said.

Full Story:

Related Summaries